- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00116272
Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project
OTIS Autoimmune Diseases in Pregnancy Project
Study Overview
Detailed Description
This pregnancy registry cohort study will be conducted by the Organization of Teratology Information Specialists (OTIS) which is a network of university and health department based telephone information centers serving pregnant women and health care providers throughout North America.
Participants in the first two cohorts are recruited concurrently from callers to OTIS centers, from health care providers and through direct to consumer marketing efforts. The source of historical controls is archived data on pregnancies that have been followed through the California Teratogen Information Service's Clinical Research Program located at the University of California San Diego.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Cohort 1 Inclusion Criteria: Eligible subjects will be currently pregnant women residing in the US or Canada who have had any exposure to etanercept for treatment of Rheumatoid Arthritis (RA), Juvenile RA, Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsoA) or Psoriasis (PsO) at any time during the first trimester of pregnancy which is defined as the period between first day of the last menstrual period (i.e., within two weeks of conception) up to and including the 12th week after the first day of the last menstrual period (LMP) - Eligible subjects must have documentation of an exposure to etanercept during the first trimester of pregnancy.
Cohort 2 Inclusion Criteria: Eligible subjects will be currently pregnant women residing in the US or Canada who have not taken etanercept or any TNF antagonist for treatment of RA, JRA, AS, PsoA or PsO at any time in the current pregnancy or within two months prior to the first day of the last menstrual period (LMP).
Cohort 3 Inclusion Criteria: Eligible subjects will be pregnant women who were residing in the US or Canada who had not been diagnosed with RA, JRA, AS, PsoA or PsO and had not been exposed to a known human teratogen during the index pregnancy.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Etanercept-Exposed
Pregnant women with a current diagnosis of rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis (AS), psoriatic arthritis (PsoA) or psoriasis (PsO) who used etanercept in the first trimester of pregnancy for any length of time.
|
Pregnant women previously exposed to etanercept during the first trimester.
Etanercept was not administered in this non-interventional study.
Other Names:
|
Diseased Controls
Pregnant women with a current diagnosis of RA, JRA, AS, PsA, or PsO who did not use etanercept or any tumor necrosis factor (TNF) antagonist during pregnancy.
|
|
Non-Diseased Historical Comparison
Pregnant women not diagnosed with RA, JRA, AS, PsoA, or PsO who did not use etanercept or any TNF antagonist at any time in pregnancy and were not exposed to any known human teratogen during pregnancy.
This cohort consists of historical controls enrolled in other pregnancy outcome studies selected to match pregnant women in the exposed cohort.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Infants With Major Birth Defects in Pregnancies Ending With Live-born Infants
Time Frame: From birth through 1 year of age
|
A major structural defect is defined as a defect which has either cosmetic or functional significance to the child (e.g., a cleft lip).
The Registry used the Metropolitan Atlanta Congenital Defects Program (MACDP) birth defect classification system, with some specified modifications that are appropriate for cohort studies as opposed to case-control studies.
|
From birth through 1 year of age
|
Percentage of Infants With Major Birth Defects in All Pregnancies
Time Frame: From birth through 1 year of age
|
A major structural defect is defined as a defect which has either cosmetic or functional significance to the child (e.g., a cleft lip).
The Registry used the Metropolitan Atlanta Congenital Defects Program (MACDP) birth defect classification system, with some specified modifications that are appropriate for cohort studies as opposed to case-control studies.
|
From birth through 1 year of age
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Infants With Any 3 or More Minor Birth Defects
Time Frame: From birth through 1 year of age
|
A minor structural defect is defined as a defect which occurs in less than 4 percent of the population but which has neither cosmetic nor functional significance to the child (e.g., complete 2,3 syndactyly of the toes).
The Registry used the Metropolitan Atlanta Congenital Defects Program (MACDP) birth defect classification system, with some specified modifications that are appropriate for cohort studies as opposed to case-control studies.
|
From birth through 1 year of age
|
Percentage of Infants With a Specific Pattern of Any 3 or More Minor Birth Defects
Time Frame: From birth through 1 year of age
|
A minor structural defect is defined as a defect which occurs in less than 4 percent of the population but which has neither cosmetic nor functional significance to the child (e.g., complete 2,3 syndactyly of the toes).
A pattern is defined as at least the same 3 specific minor malformations occurring in at least two infants in the exposed group.
|
From birth through 1 year of age
|
Percentage of Pregnancies Ending in Spontaneous Abortion
Time Frame: 9 months
|
Computed using Kaplan-Meier estimate at 20 weeks gestation, accounting for left truncation due to varying time in gestation at enrollment.
In multiple pregnancies ending in at least 1 live-born infant, the live birth outcome is included in the analysis.
In multiples ending in no live birth outcomes, the spontaneous abortion is counted as 1 event.
|
9 months
|
Percentage of Participants With Pre-term Delivery
Time Frame: 9 months
|
A pretem delivery is defined as prior to 37 weeks gestation.
Computed using Kaplan-Meier estimate at 37 weeks' gestation, accounting for left truncation due to varying time in gestation at enrollment.
Multiple births are excluded.
|
9 months
|
Gestational Age at Delivery (GAD) of Live Births
Time Frame: At birth
|
At birth
|
|
Birth Weight Among Full Term Infants
Time Frame: At birth
|
At birth
|
|
Birth Length Among Full Term Infants
Time Frame: At birth
|
At birth
|
|
Birth Head Circumference Among Full Term Infants
Time Frame: At birth
|
At birth
|
|
Percentage of Infants With Small for Gestational Age Birth Weight
Time Frame: At birth
|
Small for gestational age is defined as ≤ 10th percentile for sex and gestational age using National Center for Health Statistics (NCHS) / Center for Disease Control (CDC) growth curves.
|
At birth
|
Percentage of Infants With Small for Gestational Age Birth Length
Time Frame: At birth
|
Small for gestational age is defined as ≤ 10th percentile for sex and gestational age using National Center for Health Statistics (NCHS) / Center for Disease Control (CDC) growth curves.
|
At birth
|
Percentage of Infants With Small for Gestational Age Birth Head Circumference
Time Frame: At birth
|
Small for gestational age is defined as ≤ 10th percentile for sex and gestational age using National Center for Health Statistics (NCHS) / Center for Disease Control (CDC) growth curves.
|
At birth
|
Postnatal Weight Percentile at One Year
Time Frame: 1 year after birth
|
1 year after birth
|
|
Postnatal Length Percentile at One Year
Time Frame: 1 year after birth
|
1 year after birth
|
|
Postnatal Head Circumference Percentile at One Year
Time Frame: 1 year after birth
|
1 year after birth
|
|
Percentage of Infants at One Year of Age With Small for Gestational Age Weight
Time Frame: 1 year after birth
|
Postnatal growth deficiency defined as ≤ 10th centile for chronological age.
Age adjusted for gestational age at delivery if child was less than 12 months of age at postnatal measurement, unadjusted if ≥ 12 months of age at postnatal measurement.
|
1 year after birth
|
Percentage of Infants at One Year of Age With Small for Gestational Age Length
Time Frame: 1 year after birth
|
Postnatal growth deficiency defined as ≤ 10th centile for chronological age.
Age adjusted for gestational age at delivery if child was less than 12 months of age at postnatal measurement, unadjusted if ≥ 12 months of age at postnatal measurement.
|
1 year after birth
|
Percentage of Infants at One Year of Age With Small for Gestational Age Head Circumference
Time Frame: 1 year after birth
|
Postnatal growth deficiency defined as ≤ 10th centile for chronological age.
Age adjusted for gestational age at delivery if child was less than 12 months of age at postnatal measurement, unadjusted if ≥ 12 months of age at postnatal measurement.
|
1 year after birth
|
Percentage of Infants With Reported Serious or Opportunistic Infections Through One Year
Time Frame: From birth to 1 year
|
From birth to 1 year
|
|
Percentage of Infants Diagnosed With Any Malignancy Through One Year of Age
Time Frame: From birth to 1 year
|
From birth to 1 year
|
|
Percentage of Infants With Abnormal Results on Ages and Stages Questionnaire (ASQ)
Time Frame: 1 year after birth
|
The ASQ-3 evaluates 5 domains of development: communication, gross motor, fine motor, problem solving, and personal-social.
Each domain has a set of 6 items and parents rate the most appropriate answer for the presence of each skill: "Yes," "Sometimes," "Not Yet," with point values of 10, 5, or 0, respectively.
Each domain question set is totaled independently and compared against statistically derived cutoffs that are set at 2 standard deviations below the mean.
The percentage of infants below the cut-off or close to the cutoff (borderline) is reported.
|
1 year after birth
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: MD, Amgen
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gastrointestinal Agents
- Etanercept
Other Study ID Numbers
- 20040246
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy
-
Far Eastern Memorial HospitalCompletedCornual PregnancyTaiwan
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Ufuk UniversityNot yet recruitingPregnancy Complications | Pregnancy Loss | Pregnancy Preterm
-
Hadassah Medical OrganizationCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompletedProlonged PregnancyFrance
-
University Hospital, ToursCompleted
-
Technische Universität DresdenWithdrawnPregnancy Trimester, Second | Pregnancy Trimester, First | Pregnancy Trimester, ThirdGermany
-
Turku University HospitalUniversity of TurkuCompleted
-
Universitair Ziekenhuis BrusselMerck Serono International SAUnknownPregnancy | Pregnancy LossBelgium
-
Hopital Antoine BeclereUnknown
Clinical Trials on Etanercept
-
EMSWithdrawnRheumatoid ArthritisBrazil
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAnkylosing Spondylitis
-
LG Life SciencesCompletedHealthyKorea, Republic of
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...CompletedAnkylosing SpondylitisChina
-
Shanghai Celgen Bio-Pharmaceutical Co.,LtdUnknownPsoriasis | Plaque PsoriasisChina
-
AmgenCompletedArthritis, Rheumatoid; Arthritis, PsoriaticUnited States, Puerto Rico
-
Sun Yat-sen UniversityCompleted
-
AmgenCompletedRheumatoid Arthritis | Plaque PsoriasisUnited States, Canada
-
Samsung Bioepis Co., Ltd.CompletedRheumatoid ArthritisPoland, United Kingdom